Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FREESINUS is a fixed-dose combination medication marketed by JoY Pharma, primarily indicated for the relief of symptoms associated with sinusitis, the common cold, and upper respiratory tract conditions. It combines three active pharmaceutical ingredients: nimesulide, phenylephrine, and cetirizine. Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) that preferentially inhibits cyclooxygenase-2 (COX-2), providing analgesic and anti-inflammatory effects. Phenylephrine acts as a decongestant by stimulating alpha-1 adrenergic receptors, leading to vasoconstriction in the nasal mucosa. Cetirizine is a second-generation antihistamine that selectively antagonizes H1 receptors, reducing allergic symptoms such as rhinorrhea and sneezing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FREESINUS.